Document is current
Any future updates will be listed below
-
Authors
Christensen, Troels Dreier https://orcid.org/0000-0002-7881-7462
Buhl, Anna Sofie Kappel
Christensen, Ib Jarle
Buhl, Ida Kappel
Balslev, Eva
Knoop, Ann S.
Danø, Hella
Glavicic, Vesna
Luczak, Adam
Langkjer, Sven Tyge
Linnet, Søren
Jakobsen, Erik Hugger
Bogovic, Jurij
Ejlertsen, Bent
Rasmussen, Annie
Hansen, Anker
Knudsen, Steen
Jensen, Peter Buhl
Nielsen, Dorte
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R141-A8989-15-S7)
Innovationsfonden (5139-00026B)
- License Information
-
More Information
Article History
Received: 18 July 2019
Accepted: 16 October 2019
First Online: 25 October 2019
Compliance with ethical standards
:
: Authors IKB, ASKB, AR, AH, SK, PBJ declare current employment or leadership position in Oncology Venture, that has a potential to benefit from these results. Authors IKB (immediate family), ASKB, IJC, AR, AH, SK and PBJ declare ownership in Oncology Venture, that has a potential to benefit from these results. IJC declare consultancy role to Oncology Venture. Author BE has previously received grants from NanoString Technologies, Roche, and Novartis outside the submitted work.
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This was a retrospective non-intervention study and was not associated with any risk for participating patients and the results did not affect future treatment of the patients. The LiPlaCis study (ID H-1–2013-016) and this substudy (ID HGH-2016–097) were approved by The Copenhagen Regional Committee on Health Research Ethics.
: Informed consent was obtained from all individual participants included in the study.
: Data will be made available through applications to DBCG.
